EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia






Journal of the American College of Cardiology 5(6): 1407-1413

Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia

The effects of the antiarrhythmic agent propafenone were evaluated in 25 patients with recurrent symptomatic ventricular tachycardia. Oral propafenone was given to a maximal dose of 300 mg every 8 h. Of the 25 patients 10 developed side effects or had inadequate suppression of spontaneous ventricular arrhythmias during propafenone therapy. Electrophysiologic studies were performed before and during drug therapy on the 15 patients who had a satisfactory clinical response. Propafenone increased the PR interval from 168 .+-. 46 to 188 .+-. 25 ms (P < 0.007), the HV interval from 47 .+-. 10 to 65 .+-. 13 ms (P < 0.005), the shortest atrial pacing cycle length to maintain 1:1 atrioventricular (AV) nodal conduction from 385 .+-. 44 to 436 .+-. 42 ms (P < 0.005), the ventricular effective refractory period from 231 .+-. 17 to 255 .+-. 19 ms (P < 0.001) and the ventricular functional refractory period from 260 .+-. 15 to 278 .+-. 17 ms (P < 0.002). Before propafenone therapy, all 15 patiets had ventricular tachycardia induced by programed ventricular stimulation. During propafenone treatment, 12 patients still had ventricular tachycardia induced and the tachycardia cycle length significantly increased from 236 .+-. 44 to 374 .+-. 103 ms (P < 0.001). Ten patients were considered to have satisfactory electrophysiologic response to propafenone on the basis of either the inability to intitate ventricular tachycardia or a marked increase in ventricular tachycardia cycle length associated with lack of symptoms during the induced tachycardia. These patients were discharged receiving propafenone. During a mean follow-up period of 11 mo., 8 of the 10 patients remained free of ventricular tachycardia, while 2 had a recurrence. Propafenone significantly depresses AV nodal and His-Purkinje conduction, lengthens ventricular refractoriness and markedly increases ventricular tachycardia cycle length. Induction of ventricular tachycardia at electrophysiologic study does not always augur recurrence of spontaneous tachycardia.

Accession: 005349277

PMID: 3889099

DOI: 10.1016/s0735-1097(85)80357-0

Download PDF Full Text: Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia



Related references

Musto, B.; D'Onofrio, A.; Musto, A.; Cavallaro, C.; Marsico, F., 1986: Electrophysiologic effects and clinical efficacy of propafenone in pediatric patients with paroxysmal supraventricular reentrant tachycardia. Twenty patients (pts) with recurrent paroxysmal supraventricular tachycardia (PSVT), 12 female and 8 male, aged 9.8 +/- 4.7 years, underwent an electrophysiologic study (EPS) in order to assess the effects of propafenone (Pf) administered intraven...

Musto B.; D'onofrio A.; Cavallaro C.; Musto A.; Violini R., 1987: Electrophysiologic effects and clinical efficacy of propafenone p in children with recurrent paroxysmal supraventricular tachycardia pst. European Heart Journal 8(ABSTR SUPPL 2): 97

Connolly, S.J.; Kates, R.E.; Lebsack, C.S.; Echt, D.S.; Mason, J.W.; Winkle, R.A., 1983: Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Sixteen patients with ventricular tachycardia (VT) or nonfatal cardiac arrest were treated with propafenone (P), 900 mg/day. Electrophysiologic studies were performed before and during therapy with P. All patients had inducible sustained VT at the...

Shen, E.N.; Sung, R.J.; Morady, F.; Schwartz, A.B.; Scheinman, M.M.; DiCarlo, L.; Shapiro, W., 1984: Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. Electrophysiologic and hemodynamic studies were performed before and after intravenous infusion of a new antiarrhythmic agent, propafenone, in 28 patients with recurrent ventricular tachycardia. Propafenone was given at a loading dose of 2 mg/kg i...

Lerman, B.B.; Waxman, H.L.; Buxton, A.E.; Josephson, M.E., 1983: Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation. The efficacy of disopyramide in the management of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) was evaluated in 50 patients by programmed ventricular stimulation: 38 patients had coronary artery disease (16 with left ven...

Dugernier T.; Brugada P.; Lemery R.; Linssen G.; Della Bella P.; Wellens H.J.J., 1987: Electrophysiologic effects and clinical efficacy of flecainide in patients with ventricular tachycardia. Journal of the American College of Cardiology 9(2 SUPPL A): 71A

Kim S.G.; Felder S.D.; Waspe L.E.; Fisher J.D., 1986: Electrophysiologic effects and clinical efficacy of mexiletine in patients with refractory ventricular tachycardia. Clinical Research 34(2): 314A

Kus T.; Campa M.A.; Nadeau R.; Dubuc M.; Kaltenbrunner W.; Shenasa M., 1992: Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 .+-. 9 years) with prior myocardial infarction. Programmed stimulation consisted of two...

Niwano, S.; Yamaura, M.; Yoshizawa, N.; Moriguchi, M.; Kitano, Y.; Aizawa, Y.; Izumi, T., 1999: Electrophysiologic parameters to predict clinical recurrence of ventricular tachycardia in patients under electrophysiologic study-guided effective pharmacological therapy. Although an electrophysiologic study (EPS) is the most reliable method for selecting the treatment for a patient with sustained ventricular tachycardia (VT), VT recurrence may occur even during EPS-guided effective therapy. Electrophysiologic para...

Calvo R.; Saksena S.; Barr M.J., 1985: Electrophysiologic effects efficacy and safety of oral moricizine hydrochloride in sustained ventricular tachycardia. Clinical Pharmacology & Therapeutics 37(2): 186